Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Summary

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Conditions

• Lymphoma, Non-Hodgkin
• Multiple Myeloma
• Advanced Solid Tumors

Interventions

DRUG

Olaparib

300mg taken twice daily

DRUG

Dasatinib

100mg administered orally once daily

DRUG

Nivolumab plus Ipilimumab

* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

DRUG

Axitinib

5mg orally twice daily

DRUG

Bosutinib

500mg orally once daily

DRUG

Crizotinib

250mg orally twice daily

DRUG

Palbociclib

125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

DRUG

Sunitinib

50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

DRUG

Temsirolimus

25mg infused over a 30-60 minute period once a week

DRUG

Erlotinib

150mg orally, once daily

DRUG

Trastuzumab plus Pertuzumab

Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

DRUG

Vemurafenib plus Cobimetinib

Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

DRUG

Vismodegib

150mg taken orally, once daily

DRUG

Tucatinib

300mg taken orally, twice daily

Sponsors & Collaborators

• AstraZeneca

  collaborator INDUSTRY

• Bristol-Myers Squibb

  collaborator INDUSTRY

• Hoffmann-La Roche

  collaborator INDUSTRY

• Pfizer

  collaborator INDUSTRY

• Seagen Inc.

  collaborator INDUSTRY

• Canadian Cancer Trials Group

  lead NETWORK

Principal Investigators

• Lillian Siu · Univ. Health Network-OCI/Princess Margaret Hospital, Toronto, ON Canada

• Daniel J Renouf · BCCA - Vancouver Cancer Centre, Vancouver BC, Canada

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-03-23

Primary Completion

2026-12-31

Completion

2027-01-31

Countries

• Canada

Study Locations